This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Incyte Reports 2012 Third-Quarter Financial Results; Updates Shareholders On Launch Of Jakafi And Lead Clinical Programs

Total Revenues

Total revenues for the quarter and nine months ended September 30, 2012, were $60.5 million and $183.2 million, respectively, as compared to $16.8 million and $65.6 million, respectively, for the same periods in 2011. Included in total revenues for the quarter and nine months ended September 30, 2012, were net product revenues of $43.7 million and $92.7 million, respectively.

Included in total revenues for the nine months ended September 30, 2012, was a $40 million European Union regulatory milestone payment received from Novartis related to Jakavi. Included in total revenues for the nine months ended September 30, 2011, was a $15 million milestone payment received from Novartis related to INCB28060.

Net Loss

Net loss for the quarter ended September 30, 2012, was $21.7 million, or $0.17 per basic and diluted share, as compared to $53.1 million, or $0.42 per basic and diluted share, for the same period in 2011. Net loss for the nine months ended September 30, 2012, was $63.1 million, or $0.49 per basic and diluted share, as compared to a net loss of $131.5 million, or $1.05 per basic and diluted share, for the same period in 2011. Included in net loss for the nine months ended September 30, 2012, was a $40 million European Union regulatory milestone payment received from Novartis related to Jakavi. Included in net loss for the nine months ended September 30, 2011, was a $15 million milestone payment received from Novartis related to INCB28060.

Also included in net loss for the quarter and nine months ended September 30, 2012, were $9.5 million and $29.4 million, respectively, of non-cash expenses related to the impact of expensing employee stock options, compared to $7.4 million and $21.5 million, respectively, for the same periods in 2011.

Operating Expenses

Research and development expenses for the quarter and nine months ended September 30, 2012, were $50.1 million and $150.6 million, respectively, as compared to $44.6 million and $126.8 million, respectively, for the same periods in 2011. Included in research and development expenses for the quarter and nine months ended September 30, 2012, were non-cash expenses of $6.4 million and $19.6 million, respectively, related to the impact of expensing employee stock options, as compared to $4.8 million and $14.0 million, respectively, for the same periods in 2011.

3 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs